Literature DB >> 33163513

Clinical implications of the dual blockade of the PD-1/PD-L1 and vascular endothelial growth factor axes in the treatment of hepatocellular carcinoma.

Naoshi Nishida1.   

Abstract

Entities:  

Year:  2020        PMID: 33163513      PMCID: PMC7603925          DOI: 10.21037/hbsn.2019.10.18

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  15 in total

Review 1.  Immune checkpoint blockade for the treatment of human hepatocellular carcinoma.

Authors:  Naoshi Nishida; Masatoshi Kudo
Journal:  Hepatol Res       Date:  2018-06-06       Impact factor: 4.288

2.  Combination Cancer Immunotherapy with Molecular Targeted Agents/Anti-CTLA-4 Antibody for Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2019-01-15       Impact factor: 11.740

Review 3.  Hepatocellular Carcinoma.

Authors:  Augusto Villanueva
Journal:  N Engl J Med       Date:  2019-04-11       Impact factor: 91.245

Review 4.  Classifying Cancers Based on T-cell Infiltration and PD-L1.

Authors:  Michele W L Teng; Shin Foong Ngiow; Antoni Ribas; Mark J Smyth
Journal:  Cancer Res       Date:  2015-06-01       Impact factor: 12.701

5.  Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Carol E A Peña; Chetan D Lathia; Michael Shan; Gerold Meinhardt; Jordi Bruix
Journal:  Clin Cancer Res       Date:  2012-02-28       Impact factor: 12.531

Review 6.  Immunological landscape and immunotherapy of hepatocellular carcinoma.

Authors:  Jesús Prieto; Ignacio Melero; Bruno Sangro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-10-20       Impact factor: 46.802

Review 7.  Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.

Authors:  Rakesh K Jain
Journal:  Science       Date:  2005-01-07       Impact factor: 47.728

8.  Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.

Authors:  Abby B Siegel; Emil I Cohen; Allyson Ocean; Deborah Lehrer; Alec Goldenberg; Jennifer J Knox; Helen Chen; Sean Clark-Garvey; Alan Weinberg; John Mandeli; Paul Christos; Madhu Mazumdar; Elizabeta Popa; Robert S Brown; Shahin Rafii; Jonathan D Schwartz
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

9.  Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma.

Authors:  Mark Yarchoan; Parul Agarwal; Augusto Villanueva; Shuyun Rao; Laura A Dawson; Josep M Llovet; Richard S Finn; John D Groopman; Hashem B El-Serag; Satdarshan P Monga; Xin Wei Wang; Michael Karin; Robert E Schwartz; Kenneth K Tanabe; Lewis R Roberts; Preethi H Gunaratne; Allan Tsung; Kimberly A Brown; Theodore S Lawrence; Riad Salem; Amit G Singal; Amy K Kim; Atoosa Rabiee; Linda Resar; Yujin Hoshida; Aiwu Ruth He; Kalpana Ghoshal; Patrick B Ryan; Elizabeth M Jaffee; Chandan Guha; Lopa Mishra; C Norman Coleman; Mansoor M Ahmed
Journal:  Cancer Res       Date:  2019-09-01       Impact factor: 12.701

10.  Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort.

Authors:  Bernhard Scheiner; Martha M Kirstein; Florian Hucke; Fabian Finkelmeier; Kornelius Schulze; Johann von Felden; Sandra Koch; Philipp Schwabl; Jan B Hinrichs; Fredrik Waneck; Oliver Waidmann; Thomas Reiberger; Christian Müller; Wolfgang Sieghart; Michael Trauner; Arndt Weinmann; Henning Wege; Jörg Trojan; Markus Peck-Radosavljevic; Arndt Vogel; Matthias Pinter
Journal:  Aliment Pharmacol Ther       Date:  2019-04-12       Impact factor: 8.171

View more
  1 in total

Review 1.  Feasibility of hepatocellular carcinoma treatment based on the tumor microenvironment.

Authors:  Haiqiang Wang; Fan Shi; Shudan Zheng; Mei Zhao; Zimeng Pan; Li Xiong; Lihong Zheng
Journal:  Front Oncol       Date:  2022-09-13       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.